Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.

ABSTRACT:

Background

Determining amyloid positivity is possible with cerebrospinal fluid and brain imaging of amyloid, but these methods are invasive and expensive.

Objective

To relate plasma amyloid-β (Aβ), measured using Single-molecule array (Simoatrademark) assays, to in vivo brain Aβ, measured using positron emission tomography (PET), examine the accuracy of plasma Aβ to predict brain Aβ positivity, and the relation of APOE ɛ4 with plasma Aβ.

Methods

We performed a cross-sectional analysis in a cohort of 345 late middle-aged Hispanic men and women (age 64 years, 72% women). Our primary plasma variable was Aβ42/Aβ40 ratio measured with Simoa. Brain Aβ burden was measured as global SUVR with 18F-Florbetaben PET examined continuously and categorically.

Results

Plasma A

SUBMITTER: Rippon B 

PROVIDER: S-EPMC10361456 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature